Connor, Clark & Lunn Investment Management Ltd. Galectin Therapeutics Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$2.13 - $4.2 $35,381 - $69,766	16,611 New	16,611 $37,000
Q3 2023 Nov 13, 2023	SELL	$1.38 - $1.97 $8,119 - $11,591	-5,884 Reduced 36.93%	10,049 $19,000
Q2 2023 Aug 10, 2023	BUY	$1.32 - $2.08 $21,031 - $33,140	15,933 New	15,933 $22,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.65M

Call Options Held

1.16M

Put Options Held

1.98M

Vanguard Group Inc Valley Forge, PA

2.13M
Shares

$4.42 Million
0.0% of portfolio
Black Rock Inc. New York, NY

1.56M
Shares

$3.24 Million
0.0% of portfolio
Advisor Group Holdings, Inc. Phoenix, AZ

1.18M
Shares

$2.45 Million
0.01% of portfolio
Geode Capital Management, LLC Boston, MA

863K
Shares

$1.79 Million
0.0% of portfolio
Commonwealth Equity Services, LLC

483K
Shares

$1 Million
0.0% of portfolio

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account